| Matthew J Deorio, MD | |
|
927 Franklin St Se, Huntsville, AL 35801-4306 | |
| (256) 539-2728 | |
| (256) 539-2666 |
| Full Name | Matthew J Deorio |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 22 Years |
| Location | 927 Franklin St Se, Huntsville, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366422727 | NPI | - | NPPES |
| 7881949 | Other | AL | AETNA |
| 51042058 | Other | AL | BCBS |
| 51040155 | Other | AL | BCBS |
| Z01267 | Other | AL | VIVA HEALTHCARE |
| P00030620 | Other | AL | RAILROAD MEDICARE |
| 09-01497 | Other | AL | UNITED HEALTHCARE |
| 000102657 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 28782 (Alabama) | Secondary |
| 207XX0004X | Orthopaedic Surgery - Foot And Ankle Surgery | 28782 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Huntsville Hospital | Huntsville, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hh Health System - The Orthopaedic Center Llc | 0547624843 | 142 |
| The Orthopaedic Center | 6507757804 | 149 |
News Archive
Helix BioPharma Corp. today announced that it has completed its definitive GLP, rodent and primate, repeat-dose toxicology studies with L-DOS47. These studies demonstrated a good safety profile in an expanded number of rodent and primate test animals, building upon Helix's positive findings from its preliminary non-GLP toxicology studies.
Over the last 20 years, complications have decreased and survival has improved for extremely preterm infants, according to a study in the September 8 issue of JAMA.
A pivotal Phase III study shows Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.
MicroStockProfit.com announces an investment report featuring Imaging3 Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
› Verified 4 days ago
| Entity Name | The Orthopaedic Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205880291 PECOS PAC ID: 6507757804 Enrollment ID: O20040324000995 |
News Archive
Helix BioPharma Corp. today announced that it has completed its definitive GLP, rodent and primate, repeat-dose toxicology studies with L-DOS47. These studies demonstrated a good safety profile in an expanded number of rodent and primate test animals, building upon Helix's positive findings from its preliminary non-GLP toxicology studies.
Over the last 20 years, complications have decreased and survival has improved for extremely preterm infants, according to a study in the September 8 issue of JAMA.
A pivotal Phase III study shows Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.
MicroStockProfit.com announces an investment report featuring Imaging3 Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
› Verified 4 days ago
| Entity Name | Hh Health System - The Orthopaedic Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376220822 PECOS PAC ID: 0547624843 Enrollment ID: O20230919002679 |
News Archive
Helix BioPharma Corp. today announced that it has completed its definitive GLP, rodent and primate, repeat-dose toxicology studies with L-DOS47. These studies demonstrated a good safety profile in an expanded number of rodent and primate test animals, building upon Helix's positive findings from its preliminary non-GLP toxicology studies.
Over the last 20 years, complications have decreased and survival has improved for extremely preterm infants, according to a study in the September 8 issue of JAMA.
A pivotal Phase III study shows Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.
MicroStockProfit.com announces an investment report featuring Imaging3 Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew J Deorio, MD 927 Franklin St Se, Huntsville, AL 35801-4306 Ph: (256) 539-2728 | Matthew J Deorio, MD 927 Franklin St Se, Huntsville, AL 35801-4306 Ph: (256) 539-2728 |
News Archive
Helix BioPharma Corp. today announced that it has completed its definitive GLP, rodent and primate, repeat-dose toxicology studies with L-DOS47. These studies demonstrated a good safety profile in an expanded number of rodent and primate test animals, building upon Helix's positive findings from its preliminary non-GLP toxicology studies.
Over the last 20 years, complications have decreased and survival has improved for extremely preterm infants, according to a study in the September 8 issue of JAMA.
A pivotal Phase III study shows Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.
MicroStockProfit.com announces an investment report featuring Imaging3 Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
› Verified 4 days ago
Dr. Mark A Leberte, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 927 Franklin St, Huntsville, AL 25801 Phone: 256-539-2728 Fax: 256-428-3423 | |
Sudhakar G. Madanagopal, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 927 Franklin St Se, Huntsville, AL 35801 Phone: 256-539-2728 Fax: 256-539-2666 | |
Dr. James Turner Hughey Iii, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 927 Franklin St Se, Huntsville, AL 35801 Phone: 256-539-2728 Fax: 256-539-2666 | |
Dr. Heather Leigh Licht, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 927 Franklin St Se, Huntsville, AL 35801 Phone: 256-539-2728 | |
Dr. Michael E Miller, Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 927 Franklin St Se, Huntsville, AL 35801 Phone: 256-539-2728 Fax: 256-428-3423 | |
Dr. Randall J Tindell, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 4715 Whitesburg Dr Se, Huntsville, AL 35802 Phone: 256-881-5151 Fax: 256-880-3939 | |
Dr. Stanton B Davis Jr., MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 927 Franklin St, Huntsville, AL 35801 Phone: 256-539-2728 Fax: 256-428-3423 |